Mark joined ArchiMed in 2022 as an Operating Partner.
He has over 20 years experience in the healthcare sector; starting his career with McKinsey & Co. and later in leadership positions at sector-leading companies such as Medtronic, Parexel, and Olympus. Over the course of his career, Mark has overseen the acquisition and integration of over 20 companies and in 2017, Mark led the $5B sale of Parexel itself.
Mark has domain expertise in life sciences, medical devices, and drug development and at ArchiMed, Mark is particularly focused on investments in the Medtech space.
Mark graduated *summa cum Laude* with a BSc in Chemical and Biomolecular Engineering from the University of Arizona and holds an MBA from the Harvard Business School where he graduated with high distinction. He is also an active American Mensa member.
Mark is a US citizen and speaks fluent Spanish.